Comparison of agents using higher dose anti-VEGF therapy for treatment-resistant neovascular age-related macular degeneration.

MLA

Broadhead, Geoffrey K., et al. “Comparison of Agents Using Higher Dose Anti-VEGF Therapy for Treatment-Resistant Neovascular Age-Related Macular Degeneration.” Graefe’s Archive of Clinical & Experimental Ophthalmology, vol. 260, no. 7, July 2022, pp. 2239–47. EBSCOhost, https://doi.org/10.1007/s00417-021-05547-9.

APA

Broadhead, G. K., Keenan, T. D. L., Chew, E. Y., Wiley, H. E., & Cukras, C. A. (2022). Comparison of agents using higher dose anti-VEGF therapy for treatment-resistant neovascular age-related macular degeneration. Graefe’s Archive of Clinical & Experimental Ophthalmology, 260(7), 2239–2247. https://doi.org/10.1007/s00417-021-05547-9

Chicago

Broadhead, Geoffrey K., Tiarnan D. L. Keenan, Emily Y. Chew, Henry E. Wiley, and Catherine A. Cukras. 2022. “Comparison of Agents Using Higher Dose Anti-VEGF Therapy for Treatment-Resistant Neovascular Age-Related Macular Degeneration.” Graefe’s Archive of Clinical & Experimental Ophthalmology 260 (7): 2239–47. doi:10.1007/s00417-021-05547-9.